VolitionRx develops low-cost blood-based cancer diagnostics based on its proprietary NuQ technology, which detects the level and structure of nucleosomes in the blood using one drop of blood serum. It is currently focused on colorectal cancer (CRC), a very large opportunity with around 225 million people aged 50-75 in the US and EU eligible for screening. Data so far have suggested 84% sensitivity and 78% specificity in detecting CRC. NuQ also has the potential to detect multiple cancers. We
03 Aug 2015
A PSA-like test for multiple cancers?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A PSA-like test for multiple cancers?
VolitionRx develops low-cost blood-based cancer diagnostics based on its proprietary NuQ technology, which detects the level and structure of nucleosomes in the blood using one drop of blood serum. It is currently focused on colorectal cancer (CRC), a very large opportunity with around 225 million people aged 50-75 in the US and EU eligible for screening. Data so far have suggested 84% sensitivity and 78% specificity in detecting CRC. NuQ also has the potential to detect multiple cancers. We